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Abstract 46 
One important complication of diabetes mellitus is the chronic, non-healing diabetic 47 
foot ulcer (DFU). This study aims to develop and use dressings based on chitosan 48 
derivatives for the sustained delivery of the neurotensin (NT), a neuropeptide that act as 49 
an inflammatory modulator in wound healing. Three different derivatives, namely N-50 
carboxymethyl chitosan (CMC), 5-methyl pyrrolidinone chitosan (MPC) and N-51 
succinyl chitosan (SC), are presented as potential biomaterials for wound healing 52 
applications. Our results showed that MPC has the best fluid handling capacities and 53 
delivery profile being also non-toxic to Raw 264.7 and HaCaT cells. NT-loaded and 54 
non-loaded MPC dressings were applied into control/diabetic wounds to evaluate their 55 
in vitro/in vivo performances and the results show that the first induced a faster healing 56 
(50% wound area reduction) in the early phases of wound healing in diabetic mice. NT-57 
loaded MPC foam also reduced inflammatory cytokines expression namely TNF-α 58 
(p<0.001) and decreased the inflammatory infiltrate at day 3. At day 10, MMP-9 is 59 
reduced in diabetic skin (p<0.001) increasing significantly fibroblasts migration and 60 
collagen (COL1A1, COL1A2 and COL3A1) expression and deposition. These results 61 
suggest that MPC-based dressings may work as an effective support for a NT sustained 62 
release to modulate DFU. 63 
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Abbreviations: 79 
Collagen type I, alpha 1 (COL1A1) 80 
Collagen type I, alpha 2 (COL1A2) 81 
Collagen type III, alpha 1 (COL3A1) 82 
Diabetic foot ulcer (DFU) 83 
Ditio-bis(nitrobenzoic acid) (DTNB) 84 
Endothelial growth factor (EGF) 85 
Extracellular Matrix (ECM) 86 
 Fetal bovine serum (FBS) 87 
Glutathione (GSH)  88 
Interleukin-1β (IL-1β) 89 
Interleukin-6 (IL-6) 90 
Interleukin-8 (KC) 91 
Metalloproteinase 9 (MMP-9) 92 
N-carboxymethylchitosan (CMC) 93 
Neurotensin (NT) 94 
Nitric oxide (NO) 95 
N-succinyl chitosan (SC) 96 
Phosphate buffer solution (PBS) 97 
Platelet-derived growth factor (PDGF) 98 
Polymorphonuclear leukocytes (PMN) 99 
Scanning electron microscopy (SEM) 100 
Streptozotocin (STZ) 101 
Transforming growth factor β1 (TGF β1) 102 
Transforming growth factor β3 (TGF β3) 103 
Tumor Necrosis Factor -α (TNF-α) 104 
Vascular endothelial growth factor (VEGF) 105 
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1. Introduction 112 
Diabetes mellitus is one of the most prevalent chronic diseases worldwide. Impaired 113 
wound healing is a complication of diabetes that results in the failure to completely heal 114 
diabetic foot ulcers (DFUs) [1]. Complications of DFUs lead to frequent 115 
hospitalizations and in extreme cases, to amputations that result in elevated hospital 116 
costs and poor quality of life for patients [2]. DFU is a multifactorial complication that 117 
results particularly as a consequence of peripheral neuropathy, impaired vascular 118 
function, impaired angiogenesis and/or chronic inflammation [1, 3]. 119 
Recently, it became evident that peripheral nerves and cutaneous neurobiology 120 
contributes to wound healing [4]. Loss of peripheral sensory and autonomic nerves 121 
reduces the production of neuropeptides that are important for proper wound healing 122 
[3]. Neurotensin (NT) is a bioactive neuropeptide that is widely distributed in the brain 123 
and in several peripheral tissues [5, 6]. NT interacts with leukocytes, mast cells, 124 
dendritic cells and macrophages leading to cytokine release and chemotaxis that can 125 
modulate the immune response. In addition, NT affects microvascular tone, vessel 126 
permeability, vasodilation/vasoconstriction and new vessel formation which helps to 127 
improve angiogenesis during wound healing processes [3, 7, 8].  128 
Some studies demonstrated that topical application of neuropeptides, such as substance 129 
P and neuropeptide Y can improve wound healing in diabetes [9, 10]. However, the 130 
major problem of topical administration of peptides is their short half-life and loss of 131 
bioactivity in the peptidase-rich wound environment [11]. An alternative strategy to 132 
overcome this problem is the use of biocompatible wound dressings for the sustained 133 
delivery of neuropeptides. These dressings should however also replicate skin 134 
characteristics in order to promote the proliferation and migration of fibroblasts and 135 
keratinocytes, as well as to enhance collagen synthesis, leading to proper healing with 136 
low scar formation [12, 13].  137 
Wound dressings based on natural polymers have been extensively applied to simulate 138 
extracellular matrix (ECM) regeneration after injury [12, 13]. One of the most used 139 
natural-based polymer for wound healing applications is chitosan [12], which is a linear 140 
copolymer of D-glucosamine and N-acetyl-D-glucosamine [14]. Since it is derived from 141 
chitin, a polymer found in fungal cell walls and crustacean exoskeletons, it is a 142 
relatively inexpensive and abundant material [15]. In addition, it has proven to be 143 
biodegradable, biocompatible, non-antigenic, non-toxic, bioadhesive, anti-microbial, 144 
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bioactive and to have haemostatic capacity [15-17]. Furthermore, chitosan promotes 145 
tissue granulation and accelerates wound healing through the recruitment of 146 
inflammatory cells such as polymorphonuclear leukocytes (PMN) and macrophages to 147 
the wound site [18]. 148 
To increase its poor solubility in water, chitosan functional groups can be chemically 149 
modified to originate water soluble chitosan derivatives such as N-carboxymethyl 150 
chitosan (CMC), 5-methyl pyrrolidinone chitosan (MPC) and N-succinyl chitosan (SC) 151 
[19-21]. These chitosan derivatives are functional biomaterials that maintain the 152 
antibacterial and non-cytotoxic properties of parent chitosan. In addition, they stimulate 153 
extracellular lysozyme activity of skin fibroblasts [22, 23]. 154 
The aim of this study was to develop and apply wound dressings, prepared from the 155 
chitosan derivatives referred above (CMC, MPC, SC), for a prolonged and efficient NT 156 
delivery into diabetic and non-diabetic wounds, and also confer wound protection and 157 
comfort. The progression of skin wound healing in diabetic and non-diabetic mice was 158 
also evaluated by the analysis of the inflammatory and angiogenic effects of NT when 159 
applied in skin wounds alone or loaded into MPC-based dressings. 160 
 161 
2. Materials and methods 162 
2.1 Materials 163 
Chitosan (medium molecular weight, degree of acetylation of 90% confirmed by 1H-164 
NMR), glyoxylic acid monohydrate (98%), sodium hydroxide, sodium borohydride 165 
(99.5%), levulinic acid (98%), succinic anhydride (97%), reduced GSH, DTNB, dialysis 166 
membranes (Spectra/Por (6)) with a MWCO of 8000 Da and methanol p.a., were 167 
obtained from Sigma-Aldrich (USA). Acetic acid was obtained from Panreac (Spain), 168 
and ethanol was purchased from Riedel-de-Haen (Germany). Ketamine (Clorketam 169 
1000) was obtained from Vétoquinol (Portugal) and xylazine (Rompun) from Bayer 170 
HealthCare (Germany). NT was purchased from Bachem (Switzerland). The antibodies 171 
against TNF-α and MMP-9 were purchased from Cell Signaling Technology (USA) and 172 
the antibodies against VEGF and actin were purchased from the Millipore Corporation 173 
(USA). 174 
 175 
 176 
 177 
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2.2 Synthesis of chitosan derivatives CMC, MPC, SC 178 
Chitosan (2 g) reacted with glyoxylic acid (1,16 g), levulinic acid (5ml) or succinic 179 
anhydride (3 g) to synthesize CMC, MPC and SC respectively [24, 25], following by 180 
precipitation with ethanol and dialysis to remove unreacted reagents. Foams of CMC, 181 
MPC and SC were prepared by freeze-drying adding 1.5 ml of each solution in 12 multi 182 
well plates. The average thickness of the obtained materials was 250±15 µm. All 183 
samples were stored at −20 ºC, away from light and humidity before usage. The degree 184 
of substitution of each of the derivatives was calculated by 1H-NMR using a Bruker 185 
Avance III 400 MHz spectrometer, with a 5-mm TIX triple resonance detection probe 186 
using D2O acidified with acetic acid (10 µl of acetic acid in 600 µl of D2O).  187 
 188 
2.3 Scanning electron microscopy (SEM) 189 
SEM micrographs were obtained at 5 kV (Jeol, model JSM-5310, Japan). Samples were 190 
coated with gold (approximately 300 Å) in an argon atmosphere. 191 
 192 
2.4 Water vapor and water sorption capacities 193 
Samples of CMC, MPC and SC, with 22 mm of diameter, were dried at 37 ºC for 72 h 194 
until constant weight was achieved. Both water vapor and water sorption capacities 195 
were measured gravimetrically. In the first case, dried foams were exposed to a 95% 196 
relative humidity atmosphere, in a desiccator containing a saturated solution of 197 
potassium sulfate at 32 ºC accordingly to Dias et al, 2013 [26]. In the second case, 198 
samples were immersed into phosphate buffer (pH 7) at 37 ºC and weighted after 199 
removing the surface phosphate buffer using filter paper.   200 
Samples were weighted at fixed time intervals until they reach equilibrium. The water 201 
vapor and water sorption capacities were calculated as the ratio between sample weight 202 
at time t and sample initial dry weight. All the samples were measured in duplicate.  203 
 204 
2.5 In vitro release kinetics 205 
Kinetic release profiles of GSH were performed spectrophotometically (Jasco, model 206 
630, Japan) at 412nm. Known amounts of a GSH solution (5 mM) were loaded into 207 
previously weighted samples of each polymer. The GSH solution has been previously 208 
placed in an ultrasonic bath to avoid oxidation. After drying, samples were immersed in 209 
phosphate buffer at pH 6, 7 or 8 at 32 ºC, under orbital stirring (100 rpm) during 8 h. 210 
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The quantification of released GSH was based on the Ellman's Test. This test is based 211 
on the addition of 5,5'-dithio-bis-(2-nitrobenzoic acid) (DTNB), a yellow water-soluble 212 
compound, that reacts with free sulfhydryl groups in peptide solution. At pre-213 
determined time periods, an aliquot (100 µl) of the released solution was removed and 214 
analyzed with a mixture of 1800 µL of phosphate buffer and 100 µl of DNTB stock 215 
solution (20 mM). Fresh 100 µL of phosphate buffer was added each time point to the 216 
medium. Each sample was analyzed in duplicate.  217 
 218 
2.6 Cell culture 219 
Mouse leukaemic monocyte macrophages (Raw 264.7) and human keratinocyte 220 
(HaCaT) cells were cultured in DMEM medium, pH 7.4, supplemented with 10 % heat 221 
inactivated fetal bovine serum (FBS), 3.02 g/l sodium bicarbonate, 30 mM glucose, 100 222 
U/ml penicillin, 100 µg/ml streptomycin, at 37 ºC in a humidified incubator containing 223 
5% CO2. Sub-culturing was performed according to ATCC recommendations. Raw 224 
264.7 and HaCaT cell lines were purchased by ATCC (number TIB-71) and CLS 225 
(number 300493), respectively. 226 
 227 
2.7 MTT assay 228 
Raw 264.7 (8×104 cells/well) and HaCaT (4×104 cells/well) cells were plated 229 
individually in 12-well plates with 430 µL of DMEM, above the previously sterilized 230 
biomaterials (UV light for at least 30 minutes).  After 24 and 48 h of incubation, 43 µl 231 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution 232 
(5mg/ml) was added to each well. The plates were further incubated at 37 ºC for 1 h, in 233 
a humidified incubator containing 5% CO2. After this period, 300 µl of acidic 234 
isopropanol (0.04 N HCl in isopropanol) was added. Quantification was performed 235 
using an ELISA automatic microplate reader (SLT, Austria) at 570 nm, with a reference 236 
wavelength of 620 nm. Each sample was analyzed in duplicate. 237 
 238 
2.8 NO production – Griess Method 239 
Raw 264.7 (8×104 cells/well) cells were plated in 12-well plates with 430µL of DMEM, 240 
above the previously sterilized biomaterials (UV light for at least 30 minutes). After 24 241 
and 48 h after incubation, 170 µl of medium supernatant was mixed with an equal 242 
volume of Griess reagent (1% sulfanilamide, 0.1% N-1-naphthelenediamine 243 
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dihydrochloride in 2.5% phosphoric acid). After 30 minutes of incubation in the dark, 244 
the absorbance was measured at 550 nm in a microplate reader (SLT, Austria). Nitrite 245 
concentration was calculated from a previously obtained nitrite standard curve. 246 
 247 
2.9 In vivo wound closure 248 
We used male C57BL/6 mice (Charles River Corporation Inc, Barcelona, Spain) 249 
weighing 25-30 g. The animals were maintained at normal room temperature (22-24 °C) 250 
on a 12 h light/dark cycle, with free access to commercial pellet diet and water. After 251 
the wound procedure, the animals were kept in individual cages. All experiments were 252 
conducted according to the National and European Communities Council directives on 253 
animal care. 254 
Diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ, 150 255 
mg/kg) in citrate buffer pH 4.5. Four days after diabetes induction, blood glucose levels 256 
were checked by Accu-Chek Aviva glucometer (Roche Diagnostics GmbH, Germany). 257 
The animals with blood glucose levels higher than 300 mg/dl were considered diabetic. 258 
Mice were anesthetized by intraperitoneal injection of xylazine (13 mg/kg) and 259 
ketamine (66.7 mg/kg). The dorsal hair of control and diabetic mice was shaved and 260 
two 6 mm diameter full-thickness wounds of were created with a biopsy punch.  261 
C57BL/6 mice were randomly divided into six groups of treatment for control (non-262 
diabetic) and diabetic mice – three groups for day 3 (d3) (I, II, III) and three similar 263 
groups for day 10 (d10) (IV, V, VI): groups I and IV were treated with MPC dressings 264 
alone (6-12 animals), groups II and V with topical application of 50 µg/ml NT (7 265 
animals) and groups III and VI with 50 µg/ml NT-loaded MPC dressings (7-9 animals).  266 
For each animal one of the wounds worked as control (PBS application only) and the 267 
other received treatment. The dried MPC foams were applied over the wounds and 268 
wetted with 5 µl of PBS or NT solution (50 µg/ml) to originate hydrogels with improved 269 
adherence and mucoadhesive capacities. By visual inspection it was possible to observe 270 
that the dressings persist into the wound approximately until day 6-7. The progress of 271 
wound healing was evaluated periodically by acetate tracing till day 10. Topical 272 
application of PBS or NT (alone or loaded into the prepared MPC dressing) was 273 
performed daily. At day 3 or day 10, C57BL/6 mice were sacrificed and around 2 mm 274 
of tissue and skin surrounding the wound were harvested. These time points were 275 
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chosen to evaluate the inflammatory (day 3) and the proliferating/remodeling (d10) 276 
phases of wound healing. 277 
 278 
2.10 Real time RT-PCR  279 
Total RNA was isolated from skin with the RNeasy Mini Kit according to the 280 
manufacturer’s instructions (Qiagen, USA). First strand cDNA was synthesized using 281 
High Capacity cDNA Reverse Transcription. Then, real-time RT-PCR was performed 282 
in a BioRad MyCycler iQ5. Primer sequences are given upon request. Gene expression 283 
changes were analyzed using iQ5Optical system software v2. The results were 284 
normalized using a housekeeping gene, TATA box binding protein (TBP), which was 285 
previously validated in our lab. Quantitative RT-PCR results were analyzed through 286 
delta CT calculations. 287 
 288 
2.11 Western Blotting 289 
Skin tissue lysate was homogenized in RIPA buffer (50mM Tris HCl pH8, 150 mM 290 
NaCl, 1% NP-40, 0.5% Sodium Deoxycholate, 0.1% SDS, 2 mM EDTA, proteases 291 
inhibitor cocktail, phosphatase inhibitor cocktail and 1 mM DTT). Protein concentration 292 
was determined using the BSA method and the skin lysates were denatured at 95 ºC, for 293 
5 min, in sample buffer. 40 µg of total protein were resolved on 12% SDS-PAGE and 294 
transferred to PVDF membranes. The membranes were blocked with 5% fat-free dry 295 
milk in Tris-buffered saline containing 0.1% (v/v) Tween 20 (TBS-T), for 1 h, at room 296 
temperature. After blocking, membranes were incubated with the primary antibodies 297 
against the TNF-α (1:500), VEGF (1:1000), MMP-9 (1:500), overnight at 4 ºC. After 298 
incubation, membranes were washed and incubated for 1 h at room temperature, with 299 
anti-rabbit antibody (1:5000), or anti-mouse antibody (1:5000). The membranes were 300 
exposed to the ECF reagent followed by scanning on the VersaDoc (Bio-Rad 301 
Laboratories, Portugal). For normalization, the membranes were re-probed with an anti-302 
actin antibody (1:10000). The generated signals were analyzed using the Image-Quant 303 
TL software. 304 
 305 
2.12 Hydroxyproline content  306 
This analysis was performed using a Hydroxyproline Assay Kit (Sigma Aldrich, USA). 307 
Briefly, 10 mg of skin tissue were homogenized in 100 µl of water and hydrolyzed with 308 
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HCl 12 M at 120 ºC for 3 h. 25  µl of the supernatant were transferred to 96- well plate 309 
and evaporated in the incubator at 60 ºC till total dryness. After, 100 µL of the 310 
Chloramine T/Oxidation Buffer and 100 µL of the Diluted DMAB Reagent were added 311 
to each sample and incubated for 90 minutes at 60 ºC. Quantification was performed 312 
using an ELISA automatic microplate reader (SLT, Austria) at 560 nm.  313 
 314 
2.13 Histopathological analysis 315 
For histological preparation, the skin was fixed in 10% neutral buffered formalin and 316 
then embedded in paraffin.  Skin tissues were sectioned in 3 µm thickness slices for 317 
histopathological examination by hematoxylin/eosin (H&E) and for collagen formation 318 
by Masson’s Trichrome staining, using standard procedures. The stained sections were 319 
observed with a microscope Nikon H600L with Digital Camera DXM 1200F (Nikon, 320 
Germany). Analysis of stained skin sections was performed by an experienced 321 
pathologist.  322 
 323 
2.14 Statistical analysis 324 
Results are expressed as mean ± SEM (Structural Equation Modeling). Statistical 325 
analysis was performed using one-way ANOVA followed by Tukey’s multiple 326 
comparison tests or through the unpaired or paired t test by GraphPad Prism (GraphPad 327 
Software, Inc., San Diego, CA, USA) and p values lower than 0.05 were considered 328 
statistically significant. 329 
 330 
3. Results  331 
3.1 Degree of substitution and morphology of CMC, MPC and SC  332 
The degree of substitution (amount of native chitosan amino groups substituted) of each 333 
chitosan derivative was confirmed by 1H-NMR and it was equal to 25.5%, 24% and 334 
28.5% for CMC, MPC and SC, respectively (Figure S1 supplementary data). The 335 
schematic representation of each derivative is shown in Figure 1A. 336 
The different morphologies obtained for each of the prepared chitosan derivative foams 337 
are shown in Figure 1B. CMC presents a honeycomb-like porous structure, with larger 338 
pores than MPC and SC, which presented an interlaced fiber-like pattern. The fiber-like 339 
structure of SC seems to be thinner than the one observed for MPC.  340 
 341 
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3.2 Water vapor and water swelling properties 342 
Figure 2A shows the water vapor sorption behavior of CMC, MPC and SC foams in 343 
controlled humidity (95%) and temperature conditions (32 ºC). Data show that the 344 
hydrophilicity of the materials changes in the sequence SC > MPC > CMC. All the 345 
samples achieved equilibrium after approximately 8 hours and at this point, SC 346 
adsorbed 35% of its weight in water vapor while MPC and CMC adsorbed 24% and 347 
14%, respectively.  348 
In terms of water swelling capacity, Figure 2B shows that SC presents the fastest 349 
swelling rate, reaching its maximum (2438%) after 5 h and it starts to dissolve after this 350 
period. On the other hand, CMC presented the lowest swelling capacity (163%) while 351 
MPC has an intermediate water swelling profile. Both MPC and SC foams reach water 352 
swelling equilibrium after approximately 6 h and both maintain their structure 353 
(macroscopically, at naked eye) until day 15, at the tested experimental conditions.  354 
 355 
3.3 In vitro release kinetics  356 
Glutathione (GSH) was used as a model peptide test molecule for in vitro release 357 
kinetics studies. The release of GSH from CMC, MPC and SC foams was followed for a 358 
period of 8 h at 3 different pHs (6, 7 and 8) which is the pH range that can be observed 359 
during the wound healing process. The release profiles measured for each chitosan 360 
derivative at pH 7 are presented in Figure 3. Data measured at pHs 6 and 8 are presented 361 
as supplementary data (Figure S2) due to the similarities observed among the different 362 
pHs studied in this work. The release profiles show that equilibrium is attained between 363 
5 and 8 h for all the samples and that the amount of GSH released from SC is 364 
significantly higher than for CMC and MPC (~9 and 4 times higher, respectively). 365 
When comparing the amount of GSH released after 8 h with the total GSH loaded 366 
amount, the results show that ~50% was released from CMC and MPC while almost 367 
100% was released from SC. Obtained results also show that the amount of GSH 368 
released from the chitosan derivatives is not significantly affected in the pH range 369 
studied and considering the experimental error, being average equal to (32.33±0.72), 370 
(67.65±6.77) and (287.18±14.92) GSH released (%)/mpolymer (g) for CMC, MPC and 371 
SC, respectively.  372 
 373 
3.4 In vitro biocompatibility of CMC and MPC 374 
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There was no significant difference in the viability of the Raw and HaCaT cells exposed 375 
to CMC and MPC foams during 24, 48 and 72 h, when compared to control, as shown 376 
in Figure 4 (A and B, respectively). NO is produced by macrophages in response to an 377 
inflammatory stimuli. The production of nitrites, final stable breakdown product of NO, 378 
measured after exposure of the cells to the chitosan derivatives (Figure 4C) was also not 379 
significantly affected, however, a slight increase in the nitrites produced after 72 h was 380 
observed, which may be due to the stress to which cells are subjected after this exposure 381 
period. 382 
 383 
3.5 Wound healing experiments – in vivo 384 
Figure 5 shows the effect of the different topical treatments studied in this work: NT 385 
alone, MPC foam alone and NT-loaded MPC foam both in control (A) and diabetic (B) 386 
mice. PBS was applied as control. All treatments were shown to reduce significantly the 387 
wound area, as compared to PBS treated wounds, in both control and diabetic mice. In 388 
Figure 5 A, NT alone reduced significantly the wound size at day 3 post wounding, by 389 
22% (p<0.05), compared to the PBS treated wounds, in control mice. In diabetic mice, 390 
the wound size of the NT treated wounds is also significantly reduced at day 3, and at 391 
day 5 by 29% (p<0.01) and 34% (p<0.01), respectively. A different healing profile is 392 
observed for the non-loaded and NT-loaded MPC treated wounds either in control and 393 
diabetic mice. A significant decrease in the wound area is evident at day 1 post 394 
wounding in non-loaded MPC by 48% (p<0.001) and in NT-loaded MPC, by 43% 395 
(p<0.001), when compared with PBS-treated wounds (Figure 5A). In diabetic animals, 396 
the profile of wound closure was similar, however the NT-loaded MPC treatment was 397 
significantly more effective than MPC alone, with a wound reduction of 50% (p<0.001) 398 
instead of 35% (p<0.001) of closure for the non-loaded dressing (Figure 5B). 399 
 400 
3.6 Cytokine, MMP-9, collagen types and growth factors expression at the wound 401 
site 402 
In order to address the pattern of cytokine gene expression in untreated or treated 403 
wounds at 0, 3 and 10 days post-wounding, the gene expression for inflammatory 404 
cytokines (TNF-α, IL-6, KC, IL-1β) and several types of collagen genes (COL1A1, 405 
COL1A2, COL3A1) were measured and the results are presented in Figure 6 A-N. 406 
Other important factors such as MMP-9, growth factors (EGF, VEGF, PDGF), TGFβ1, 407 
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TGFβ3 were also evaluated and its expressions are presented in Figure S3 408 
Supplementary data.  409 
In unwounded skin (day 0, baseline), all the measured inflammatory cytokines were 410 
significantly increased in the skin of diabetic animals compared with the healthy 411 
controls (Figure 6 A-G). On the other hand, all types of collagens analyzed are 412 
significantly reduced (p<0.001) (Figure 6 I-N, respectively).  413 
We observed a significant increase, at day 3 post-wounding, in the inflammatory 414 
stimulus, as one might expect, when compared to day 0 in controls. However, the same 415 
effect is not observed in diabetic mice. 416 
Furthermore, at day 3, in control mice, the MPC treatment alone reduced significantly 417 
the expression of TNF-α (p<0.05), IL-6 (p<0.05) and IL-1β (p<0.05) while the NT 418 
alone decreased the expression of TNF-α (p<0.05) and IL-1β (p<0.05) (Figure 6 A, C 419 
and G, respectively).  In addition, the NT-loaded MPC treatment reduced the TNF-α 420 
expression (p<0.05), however the IL-6 and KC expression significantly increased in the 421 
controls (p<0.05). In diabetic mice, the TNF-α expression was significantly higher for 422 
all treatments (p<0.05) but the IL-1β expression is reduced upon the NT-loaded MPC 423 
treatment (p<0.05) compared with PBS alone.  424 
Moreover, at day 3, NT alone reduced the EGF expression in diabetic mice (p<0.05) 425 
and increased the VEGF expression (p<0.05) in the control (Figure S3 C and E). In 426 
addition, while NT and NT-loaded MPC foam significantly induced TGFβ3 expression 427 
(p<0.001), in controls, no differences where observed in diabetic skin (Figure S3 K). 428 
Collagen genes were more expressed in control skin and NT treatment significantly 429 
increased COL1A1, COL1A2 and COL3A1 expression in diabetic skin (Figure 6 I, K 430 
and M, respectively). 431 
At day 10, the expression of all the inflammatory cytokines was diminished to baseline 432 
levels in the controls, with the exception of TNF-α that increase (p<0.05) with NT and 433 
the NT-loaded MPC application, compared to PBS treated wounds. In diabetic mice, all 434 
the treatments reduced the expression of TNF-α, IL-6 and KC (p<0.05 in all cases) 435 
(Figure 6 B, D and F, respectively). The non-loaded and the NT-loaded MPC treatments 436 
caused a decrease in the MMP-9 expression in both control and diabetic mice (p<0.05) 437 
(Figure S3 B). In addition, the NT-loaded MPC treatment reduced EGF in diabetic 438 
mouse skin (p<0.05) (Figure S3 D).  439 
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NT and NT-loaded MPC foam significantly induced TGFβ1 and TGFβ3 expression 440 
(p<0.001) in controls at day 10 but no differences where observed in diabetic skin. In 441 
diabetic skin, only NT treatment reduced significantly TGFβ3 (p<0.05) (Figure S3 J, L). 442 
In addition, NT and NT-loaded MPC foam highly stimulated an increase in COL1A1 443 
and COL1A2 (p<0.001) in control mice while in diabetic mice only NT-loaded MPC 444 
significantly induced expression of all collagen genes (Figure 6 J, L,N). 445 
 446 
3.7 Protein expression in the wound site 447 
To evaluate protein expression levels at the wound site, Western Blot analysis of skin 448 
tissue was performed (Figure 7). At day 0, only MMP-9 is significantly increased 449 
(p<0.001) in diabetic mice when compared to controls. At day 3, NT treatment induced 450 
a reduction of MMP-9 protein levels in control mice. Moreover, in diabetic wounds, 451 
MPC treatment increased TNF-α level. In contrast, NT and NT-loaded MPC foam 452 
significantly reduced MMP-9 (p<0.05) and TNF-α (p<0.001) protein levels, 453 
respectively.  454 
At day 10, MPC, NT or NT-loaded MPC treatments significantly reduced MMP-9 455 
protein expression comparing with PBS treatment, either in control or diabetic skin. In 456 
addition, TNF-α protein expression was not detected in all treatments at day 10, by 457 
Western Blot.   458 
 459 
3.8 Hydroxyproline content in the wound site 460 
To evaluate collagen deposition in mouse skin, hydroxyproline levels were measured in 461 
unwounded and wounded (treated and non-treated) skin (Figure 8). In unwounded skin, 462 
hydroxyproline levels were significantly decreased (p<0.01) in diabetic mice comparing 463 
with control skin. At day 3 post-wounding, NT significantly increased (p<0.05) 464 
hydroxyproline content in diabetic skin, while at day 10, this effect was observed with 465 
NT-loaded MPC in control and diabetic skin (p<0.05, p<0.01), respectively. 466 
 467 
3.9 Histopathological analysis of the wound 468 
For the histopathological analysis of control and diabetic skin tissue we used the H&E 469 
and Masson´s Trichrome staining (Figures 9A and B, respectively). In unwounded skin 470 
the increase in the epidermis skin thickness was evident in diabetic mice when 471 
compared with control. At day 3 post wounding, all the treatments stimulated an 472 
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increase in the epidermis thickness which was more significant for the non-loaded and 473 
NT-loaded MPC treatments in diabetic skin (Table 1).  At day 10, the epidermis 474 
thickness profile was similar with a stronger effect in diabetic skin (Figure 9A – 3), 475 
(Table 2). A specific re-epithelialization profile was observed: in control mice, re-476 
epithelialization occurred from bottom to top with basal cells in the epidermis covering 477 
the scar. In diabetic mice, the re-epithelialization occurred over the granulation 478 
inflammatory tissue while this was suffering repair, without correlation with the applied 479 
treatments, in both groups (Table 2 and 3).   480 
At day 3, neither MPC, NT alone or NT-loaded MPC treatments affected the number of 481 
polymorphonuclear leukocytes (PMN) and lymphocytes in control skin, however in 482 
diabetic skin, these inflammatory cells were less recruited to the wound site compared 483 
with the PBS treatment. In addition, there is higher production of fibrin in diabetic skin 484 
while no plasma cells were observed in either control or diabetic skin (Table 3). At day 485 
10, there was no significant recruitment of PMN and lymphocytes observed in control 486 
skin, while in diabetic wounds treated with either MPC, NT alone or NT-loaded MPC, 487 
PMN cells, lymphocytes and plasma cells were present in higher numbers when 488 
compared with PBS treatment. It is important to note that inflammatory cells persisted 489 
at day 10 especially in the diabetic wounded skin. No fibrin was observed either in 490 
control or diabetic skin (Table 4). Fibroblasts, which are important for tissue repair, 491 
were increased in diabetic when compared to control wounded skin, at day 3. Moreover, 492 
collagen matrix production appeared to be more evident in diabetic skin, particularly 493 
after the NT or the NT-loaded MPC foam treatment. However, the scar was more 494 
pronounced in these treatments (Table 3). Furthermore, at day 10, NT-loaded MPC 495 
foam induced the migration of fibroblasts and the production of the collagen matrix. 496 
However, the scar obtained after this treatment was more pronounced (Table 4). A 497 
summary of cytokine expression and corresponding cell type production, in wounded 498 
control and diabetic skin, at either day 3 or 10 post-wounding, is represented on table 5.  499 
 500 
4. Discussion 501 
One of the main objectives of this work was to evaluate the capacity of chitosan-based 502 
wound dressings to work as biocompatible and biodegradable supports for the sustained 503 
delivery of neurotensin (NT), a neuropeptide that has shown to improve wound healing 504 
[27, 28].  505 
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Three different water soluble chitosan derivatives (CMC, MPC and SC) were 506 
synthesized and tested for their water swelling capacities and peptide release profiles in 507 
order to infer which of the derivatives would present the best performance (controlled 508 
swelling and NT delivery over time) in vivo. At this stage, GSH was used as a model 509 
peptide. Although GSH presents lower molecular weight than NT, it has similar 510 
functional groups that will permit the simulation of the physical and chemical 511 
interactions that may be established between the molecule and the material used as the 512 
dressing.  513 
The obtained results showed that the SC foam has the highest water vapor and water 514 
swelling capacity probably due to the high number of thin fibers that constitute its 515 
matrix, increasing the contact area between the material and the water molecules. The 516 
higher affinity of SC for water (higher hydrophilicity) justifies its faster dissolution in 517 
PBS. These results are also in agreement with the 1H-NMR data that showed a higher 518 
degree of substitution for SC. This was expected since chitosan substitutions performed 519 
in this work aimed to improve the solubility of chitosan in aqueous media. According to 520 
the water swelling results, MPC presented an intermediate swelling profile, despite the 521 
apparent larger porosity of the CMC derivative observed by SEM analysis.  522 
Medicated wound dressings have been largely used to deliver healing enhancers and 523 
therapeutic substances, such as growth factors or stem cells to stimulate wound healing 524 
[29, 30]. Their use allows the protection of the wound against external aggression and 525 
avoids the rapid biodegradation of the bioactive healing enhancers that may occur in the 526 
enzyme rich wound environment. In this work, the capacity of each dressing to sustain 527 
the release of a peptide at different pH conditions was addressed. The measured release 528 
kinetics performed was not significantly affected within the pH ranges studied and SC is 529 
the material that presented the faster release of GSH, followed by MPC and CMC. The 530 
release profiles are in accordance with the water swelling profiles observed for the 531 
different chitosan derivatives, indicating that the GSH release is mainly controlled by 532 
the water swelling capacity of the material and therefore GSH is released mainly 533 
through a diffusion mechanism. The higher swelling capacity of SC leads to a higher 534 
amount of water inside the polymer structure, better dissolving GSH, enhancing its 535 
release into the surrounding medium. According to these results (water swelling and 536 
GSH release data), and considering that sustained profiles were envisaged for in vivo 537 
applications, the use of SC based material was discarded at this stage.  538 
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The biocompatibility of CMC and MPC foams was tested in vitro, in Raw 264.7 and 539 
HaCaT cell lines and the results showed that both materials were non-toxic against these 540 
cell lines, up to 48 h. For the 72 h test period, a slight decrease (not statistically 541 
significant) in the viability of the cells was observed probably due to foam dissolution 542 
or cell stress in the media conditions. Similar results were observed in L929 cells 543 
(fibroblast cell line) by Huang and colleagues [31]. The production of nitrites by 544 
macrophages Raw 264.7 was also quantified since it is known that these cells produce 545 
NO when stimulated by inflammatory stimulus. The results presented show that CMC 546 
and MPC do not increase nitrite levels in vitro suggesting that these compounds do not 547 
induce an inflammatory response which is in accordance with data previously reported 548 
in the literature [32]. The in vitro results indicate that both CMC and MPC could be 549 
used for wound dressing applications. However, in this work, in vivo application and 550 
characterization was performed only for MPC, which was the material that presented an 551 
intermediate GSH release profile compared to either CMC or SC.   552 
Several studies suggested that chitosan and derivatives accelerate wound healing [33, 553 
34]. For instance, MPC freeze-dried foams were shown to jellify in contact with 554 
biological fluids, being progressively absorbed via enzymatic hydrolysis, promoting 555 
regeneration of connective tissues [35]. However, no further studies were found in the 556 
literature reporting the effect of MPC alone or in combination with NT in diabetic 557 
wound healing.  558 
Diabetes mellitus cause important complications, namely at skin level. The healing 559 
process involves several overlapping phases: homeostasis/coagulation, inflammation, 560 
proliferation (granulation tissue formation), re-epithelialization and remodeling [36]. 561 
All these processes require the interaction of skin cells, cytokines and growth factors 562 
released from inflammatory cells, fibroblasts, keratinocytes and epithelial cells [2].  563 
Due to the fact that mouse skin is elastic and has lack of a strong adherence to the 564 
underlying structures, wound contraction is usually more rapid than epithelialization 565 
which causes a decrease in the overall healing time of mice wounds [37]. Wound 566 
closure results show that NT induced a faster closure in diabetic mice, even when 567 
applied directly over the wound and compared with control mice. This was expected 568 
since it has been reported that topical application of neuropeptides, such as Substance P, 569 
stimulate diabetic wound healing [9]. In addition, previous studies in our group 570 
observed that NT modulates inflammatory responses in a skin dendritic cell line [28].  571 
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Treatments with non-loaded and NT-loaded MPC foams induced a significant reduction 572 
of the wound area, especially in the first 3 days post-wounding and in both control and 573 
diabetic mice. Moreover, NT-loaded MPC presented a faster healing profile in diabetic 574 
skin wounds. These results suggest a synergistic behavior between the bioactivity of NT 575 
alone and the intrinsic healing properties of MPC. Moreover and as intended, a 576 
sustained release of NT may also occur which guarantees controlled NT levels during 577 
the healing process. The adhesive properties of chitosan and its derivatives could 578 
explain this enhanced healing profile [38]. In addition, wound contraction is necessary 579 
for the healing process, probably due to the enhanced proliferation of fibroblasts due to 580 
arising contractile myofibroblasts [39]. Wound contraction is a biologically important 581 
process in wound healing, especially in the healing of chronic wounds such as DFU, 582 
although excessive contraction may lead to scar formation [40]. All treatments lead to 583 
healing however, larger scars were developed over diabetic wounds that were treated 584 
with MPC foams, most probably due to the fast initial wound contraction verified in this 585 
case.    586 
In unwounded diabetic skin, an overexpression of inflammatory cytokines, growth 587 
factors and MMP-9 was observed, which is in agreement with the literature [41]. These 588 
results suggest a chronic pro-inflammatory state in diabetic skin that can compromise 589 
the wound healing. On the other hand, the gene expression of the different types of 590 
collagen is down regulated in the diabetic skin suggesting a decreased capacity of the 591 
diabetic skin to produce the appropriate matrix essential for wound healing and skin 592 
repair. As decreased expression of COL1A1, COL1A2 and COL3A1 is verified, less 593 
collagen is deposited as observed by the hydroxyproline assay [42].  594 
In chronic diabetes, the healing process becomes stalled in one or more of the healing 595 
phases originating chronic non-healing wounds. One important phase that can become 596 
stalled in diabetes is the inflammatory phase [1]. TNF-α, IL-6, KC and IL-1β are 597 
inflammatory cytokines involved in the recruitment of cells, such as neutrophils and 598 
macrophages to the wound site, to stimulate the immune response. In the skin, TNF-α 599 
produced by inflammatory cells and fibroblasts stimulates adhesion molecules and 600 
chemokines leading to attachment of inflammatory cells to vessels, rolling, migration, 601 
and eventually chemotaxis into the skin [43]. Moreover, IL-6 and IL-1β, produced by 602 
macrophages, fibroblasts, keratinocytes and epithelial cells are also important players in 603 
the early phase of inflammation and in the wound healing process [44]. In control mice, 604 
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the reduction of TNF-α and IL-1β expression with all treatments, at day 3, suggests a 605 
decrease in the inflammatory condition which facilitates healing. In diabetic mice 606 
treated with MPC, NT or NT-loaded MPC, less infiltrated inflammatory cells was 607 
observed at day 3 comparing with control mice, while TNF-α expression is significantly 608 
higher, especially for the MPC alone. Moreover, IL-6 and KC expression is 609 
significantly reduced. These results may suggest that high expression of TNF-α is 610 
produced not only by inflammatory cells present at the wound site, but also by other 611 
cells present at day 3, which can stimulate contraction of the wound and consequently 612 
have a beneficial effect in the early stages of wound healing. This may further indicate 613 
that in diabetic mice, treated with NT or/and MPC, the granulation tissue fills the 614 
wound bed potentiated by the proliferation of skin fibroblasts, in the early phase of 615 
wound healing.  616 
Similar results were observed when using MPC alone as treatment. However, NT-617 
loaded MPC treatment induced a decrease in the TNF-α protein content suggesting that 618 
the combination of NT with the MPC foam has an effective anti-inflammatory role in 619 
wound healing.  620 
At day 10, the inflammatory status persisted in diabetic mice while in controls it is 621 
resolved, as expected [4]. On the other hand, all treatments lead to a reduction in the 622 
inflammatory cytokines expression supported by the loose conjunctive tissue observed 623 
from the beginning, undergoing different status of collagen deposition in diabetic and 624 
control mice. At this time point, fibroblasts have an important role in collagen synthesis 625 
and scar formation [45, 46]. During the re-epithelialization phase, the initial ECM is 626 
gradually replaced by a collagenous matrix with the formation of new blood vessels 627 
[47]. The expression of angiogenic factors, VEGF and PDGF, did not change with 628 
treatments in diabetic mice possibly showing that these treatments do not stimulate the 629 
production of growth factors to improve wound healing. 630 
Our results show that the production of the collagen matrix was higher for MPC and 631 
NT-loaded MPC treated diabetic skin, which is correlated with increased scar 632 
formation. Obara and colleagues [29] also observed that application of a chitosan 633 
hydrogel in diabetic wounds increased scar formation. Moreover, MMP-9 expression in 634 
diabetic skin wound was increased at day 3. Most importantly, at day 10, it is observed 635 
a decrease of MMP-9 in NT-loaded MPC treated diabetic wounds, while no significant 636 
effect is observed in control wounds.  Possibly, MMP-9 may affect ECM proteolytic 637 
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enzymes, allowing the migration of cells into the wound site, which results in the 638 
deposition of new ECM and the development of new tissue. However, it is known that 639 
the increased presence of TNF-α in diabetes could reduce the MMP-9/TIMP-2 balance 640 
production by fibroblasts, contributing to the elevated proteolytic activity impairing 641 
wound healing [48].  642 
As expected, and in agreement with the literature [49], type 1 collagen was the most 643 
expressed form of collagen in the skin, serving as the framework for connective tissues 644 
such as skin, bone and tendons. This result also agrees with the observed increase in the 645 
expression of TGF (Figure S3 supplementary data) which has an important role in the 646 
pathophysiology of tissue repair by the enhancement of type 1 collagen gene expression 647 
[50]. 648 
In addition, at day 3, we observed an increased expression of all types of analyzed 649 
collagen in control compared to diabetic skin at the same time point and the opposite is 650 
verified at day 10 suggesting that diabetes impair collagen gene expression and 651 
deposition in the skin [51]. Moreover, the NT-loaded MPC foam stimulated COL1A1, 652 
COL1A2 and COL3A1 expression at day 10 in diabetic skin, which is also correlated 653 
with higher collagen production observed by the hydroxyproline content and the 654 
Masson´s Trichrome staining. 655 
 656 
5. Conclusions 657 
The results obtained in this work show that, in control animals, both MPC and NT-658 
loaded MPC foams have great impact on the early phases of the healing process 659 
decreasing the inflammatory infiltrate. In diabetic animals, the major healing effects 660 
were observed with either NT alone or NT-loaded MPC foams thus confirming the 661 
potential healing effect of NT in diabetic wound. These treatments reduced the 662 
inflammatory status in the early phase of wound healing and increased migration of 663 
fibroblast and collagen expression and deposition for tissue repair. However, a more 664 
pronounced scar was observed with the application of MPC. Table 5 summarizes 665 
cytokine expression in wounded control and diabetic skin, at day 3 and 10 post-666 
wounding. 667 
These results suggest that in vivo NT combined with the MPC foam application in 668 
diabetic wound dressings can promote an inflammatory response was able to reduce the 669 
inflammatory response, to promote an anti-inflammatory response and to stimulate re-670 
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epithelialization which are important phases of the healing process. Human studies are 671 
needed to further investigate the potential application of NT-loaded MPC wound 672 
dressings as therapy for diabetic foot ulcers. 673 
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Figures Captions 835 
 836 
Figure 1. A) Chemical synthesis of chitosan derivatives: N-carboxymethyl chitosan 837 
(CMC), 5-methyl pyrrolidinone chitosan (MPC) and N-succinyl chitosan (SC). B) SEM 838 
micrographs for non-loaded chitosan derivatives CMC, MPC and SC representing the 839 
different structures obtained by freeze-drying. Inner images represent magnifications.  840 
 841 
Figure 2. Water vapor (A) and water (B) swelling profiles observed for CMC (■), MPC 842 
(▲) and SC (♦) foams. The inserted figure represents a zoom of the water swelling 843 
profiles for the first monitored day. Lines serve only as guides for the eye. Results are 844 
presented as mean ± SEM of two independent experiments.  845 
 846 
  
25 
 
Figure 3. Release kinetic profiles for GSH from CMC (■), MPC (▲) and SC (♦) foams 847 
at pH 7 measured for 8 h at 37 ºC. Lines serve only as guides for the eye. Results are 848 
presented as mean ± SEM of two independent experiments.  849 
 850 
Figure 4. Cell viability of Raw (A) and HaCaT (B) cells in the presence of CMC or 851 
MPC foams, during 24, 48 and 72 h. and NO production in Raw cells (C). Results are 852 
presented as mean ± SEM of three independent experiments.  853 
 854 
Figure 5. Wound size measurements for MPC, NT and NT-loaded MPC foam 855 
treatments in either control (A) or diabetic (B) mice. The wound size was determined at 856 
days 0, 1, 3, 5, 8 and 10 post-wounding. Results are presented as mean ± SEM of seven 857 
to eighteen independent experiments. *p < 0.05 MPC compared to PBS, **p < 0.01 858 
MPC compared to PBS, *** p < 0.001 MPC compared to PBS, # p < 0.05 MPC+NT 859 
compared to PBS, ## p < 0.01 MPC+NT compared to PBS, ### p < 0.001 MPC+NT 860 
compared to PBS, $ p < 0.05 NT compared to PBS, $$ p < 0.01 NT compared to PBS; 861 
§p < 0.05 NT compared to MPC+NT, §§ p < 0.01 NT compared to MPC+NT, && p < 862 
0.01 MPC compared to MPC+NT. 863 
 864 
Figure 6. The gene expression profile for TNF-α, IL-6, KC, IL-1β, COL1A1, COL1A2 865 
and COL3A1  in skin biopsies before and after treatments, at either day 3 (A, C, E, G, I, 866 
K, M)  or 10 (B, D, F, H, J, L, N) post wounding. Results are presented as mean ± SEM 867 
of seven to eighteen independent experiments. & p < 0.05 compared with PBS d3, *p < 868 
0.05 compared with PBS d10, **p < 0.01 compared with PBS d10§ p < 0.05 compared 869 
with diabetic PBS d3, # p < 0.05 compared with diabetic PBS d10, # #p < 0.01 870 
compared with diabetic PBS d10. 871 
 872 
Figure 7. Protein expression of TNF-α and MMP-9 in unwounded skin (day 0) or after 873 
treatments, at either day 3 or 10 post-wounding. Results are presented as mean ± SEM 874 
of three to five independent experiments. & p < 0.05 compared with PBS d3, *p < 0.05 875 
compared with PBS d10, **p < 0.01 compared with PBS d10§ p < 0.05 compared with 876 
diabetic PBS d3, # p < 0.05 compared with diabetic PBS d10, # #p < 0.01 compared 877 
with diabetic PBS d10. 878 
 879 
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Figure 8. Hydroxyproline content levels in unwounded skin (d0) or after treatments, at 880 
either day 3 or 10 post-wounding. Results are presented as mean ± SEM of four to six 881 
independent experiments. *p < 0.05 compared with PBS d10, § p < 0.05 compared with 882 
diabetic PBS d3, # #p < 0.01 compared with diabetic PBS d10. 883 
 884 
Figure 9. Histopathological analysis of Hematoxicilin and Eosin (H&E) (Figure 9A) 885 
and  Masson´s Trichrome (Figure 9B) staining for control and diabetic mouse skin, 886 
untreated or treated with MPC, NT and NT-loaded MPC foams (magnification 100×). 887 
Representative images of three skin stainings analyzed. a) Different repair process: in 888 
diabetic wounds, the granulation tissue is retained in dermis with overgoing fibroblast 889 
proliferation, at day 3 post-wounding (H&E;magnification 200×); b) Infiltrated PMN 890 
and lymphocytes in the granulation tissue in control mice, at day 3 post-wounding 891 
(H&E; magnification: 200×); c) Persistent inflammatory cells (neutrophils and lympho-892 
plasmocitic cells) in PBS-treated diabetic mice, at day 10 post-wounding (H&E; 893 
magnification: 200×); d) Less inflammatory cells in granulation tissue when compared 894 
with c) in MPC-treated wounds, at day 10 post-wounding (H&E; magnification:200×); 895 
e) Less deposition of collagen in PBS-treated diabetic mice, at day 10 post-wounding 896 
(Masson´s Trichrome; magnification:200×); f) The granulation tissue is formed mainly 897 
by thin collagen fibers parallel to the epidermis (Masson´s Trichrome). 898 
 899 
Supplementary data S1: 1H-RMN spectra of chitosan, CMC, MPC and SC foams. 900 
 901 
Supplementary data S2: Release kinetic profiles for GSH from CMC (■), MPC (▲) and 902 
SC (♦) foams at pH 6 (A) and 8 (B) measured for 8 h at 37 ºC. Lines serve only as 903 
guides for the eye. Results are presented as mean ± SEM of two independent 904 
experiments.  905 
 906 
Supplementary data S3: The gene expression profile for MMP-9, EGF, VEGF ,PDGF, 907 
TGFβ1 and TGFβ3, in skin biopsies before and after treatments, at either day 3 (A, C, 908 
E, G, I, K)  or 10 (B, D, F, H, J, L) post wounding. Results are presented as mean ± 909 
SEM of seven to eighteen independent experiments. & p < 0.05 compared with PBS d3, 910 
*p < 0.05 compared with PBS d10, **p < 0.01 compared with PBS d10§ p < 0.05 911 
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compared with diabetic PBS d3, # p < 0.05 compared with diabetic PBS d10, # #p < 912 
0.01 compared with diabetic PBS d10. 913 
 914 
  
List of tables 
 
Table 1: Histological analysis of unwounded skin and NT, MPC and NT loaded MPC foams treated wounds at day 3, by H&E staining. - absence or no alterations, + 
presence <10%, ++ presence 10%,-50%, n.a, not applicable 
 
 
 
 
 
 
 
Table 2: Histological analysis of NT, MPC and NT loaded MPC foams treated wounds at day 10, by H&E staining. - absence or no alterations, + presence <10%, ++ presence 
10%,-50%, +++ presence >50% 
 Day 10 
 PBS MPC NT MPC+NT 
 Control Diabetic Control Diabetic Control Diabetic Control Diabetic 
New epidermis thickness 
- Stratus lucidum ++ +++ + ++ ++ +++ + ++ 
- Epithelial layers ++ +++ + ++ ++ +++ + ++ 
- Basal layer ++ +++ + ++ ++ +++ + ++ 
Wound area (mm2) 9.02±0.15 13.39±0.31 4.22±0.09 12.11±0.20 7.05±0.30 9.12±0.30 5.88±0.12 9.77±0.29 
Re-epithelization 
- From bottom + - + - + - + - 
- Top cover - + - + - + - + 
 
 Day 3 
 
Skin control (d0) PBS MPC NT MPC+NT 
 Control Diabetic Control Diabetic Control Diabetic Control Diabetic Control Diabetic 
New epidermis thickness 
- Stratus lucidum - + - + + ++ - + + ++ 
- Epithelial layers - + - + + ++ - + + ++ 
- Basal layer - + - + + ++ - + + ++ 
Wound area (mm2) 26.48 ±4.22 27.71±5.41 30.30±0.17 29.02±0.32 18.68±0.12 22.64±0.22 24.53±0.31 20.95±0.34 17.80±0.18 16.68±0.17 
Re-epithelization 
- From bottom na na + - + - + - + - 
- Top cover na na - + - + - + - + 
  
Table 3: Inflammatory and  granulation tissue histological analysis of NT, MPC and NT loaded MPC foams treated wounds at day 3, by H&E and Masson´s Trichrome 
staining. - absence or no alterations, + presence <10%, ++ presence 10%,-50%, +++ presence >50%; < not relevant, > predominant 
 
 
 
 
 
 
 
 
Table 4: Inflammatory and  granulation tissue histological analysis of NT, MPC and NT loaded MPC foams treated wounds at day 10, by H&E and Masson´s Trichrome 
staining. - absence or no alterations, + presence <10%, ++ presence 10%,-50%, +++ presence >50%; 
 Day 10 
 PBS MPC NT MPC+NT 
 Control Diabetic Control Diabetic Control Diabetic Control Diabetic 
Inflammation Status 
- PMN - ++ - + - + - + 
- Lymphocytes + +++ + ++ + ++ + ++ 
- Plasma cells + +++ + ++ + ++ + ++ 
- Fibrin - - - - - - - - 
Repair 
- Fibroblasts ++ + + ++ + + + +++ 
Collagen matrix 
- Loose - - - - - - - - 
 -      Scar ++ + + ++ + + + +++ 
 Day 3 
 PBS MPC NT MPC+NT 
 Control Diabetic Control Diabetic Control Diabetic Control Diabetic 
Inflammation Status 
- PMN ++ +++ ++ + ++ + ++ + 
- Lymphocytes + ++ + - + - + - 
- Plasma cells - - - - - - - - 
- Fibrin < > > < > < > < 
Repair 
- Fibroblasts < > < > < > < > 
Collagen matrix 
- Loose - - - + + + + - 
       -      Scar - - - + - + + ++ 
  
Table 5:  Summary of cytokine and protein expression in wounded control and diabetic skin, at day 3 and 10 post-wounding.  
Day Cytokine/Growth factor Control mice Diabetic mice Cell type that produce this protein 
TNF-α ↓ MPC, NT, MPC+NT ↑ NT, MPC+NT Macrophages, fibroblasts 
IL-6 ↓ MPC; ↑ MPC+NT ↓ MPC, NT, MPC+NT Macrophages, fibroblasts, Keratinocytes, endothelial cells 
KC ↑ MPC+NT ↓ MPC, NT, MPC+NT Macrophages, fibroblasts 
IL-1β ↓ MPC, NT, MPC+NT = MPC, NT, MPC+NT Macrophages, epithelial cells 
COL1A1 = ↑ NT Fibroblasts 
COL1A2 = ↑ NT Fibroblasts 
3 
COL3A1 ↑ MPC+NT ↑ NT Fibroblasts 
TNF-α ↑ NT, MPC+NT ↓  NT, MPC+NT Macrophages, fibroblasts 
IL-6 = ↓ MPC, NT, MPC+NT Macrophages, fibroblasts, keratinocytes, endothelial cells 
KC = ↓ MPC, NT, MPC+NT Macrophages, fibroblasts 
IL-1β   Macrophages, epithelial cells 
COL1A1 ↑NT,MPC+NT ↑MPC+NT Fibroblasts 
COL1A2 ↑NT,MPC+NT ↑MPC+NT Fibroblasts 
10 
COL3A1 ↑NT ↑MPC+NT Fibroblasts 
 
  
  
  
  
  
  
  
  
  
  
  
  
